Vulva (including Skin of Vulva) (excluding Malignant Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas)

Primary Site Histology Staging Type
C510-C512, C518-C519 8000-8246, 8248-8576, 8940-8950, 8980-8981 TNM 7 and Summary Stage
C510-C512, C518-C519 8577-8713, 8800-8939, 8951-8979, 8982-9136, 9141-9582 Summary Stage only

If you are working with a site/histology that only summary stages and you need to directly code it, please use the SEER Summary Stage 2000 manual

Notes

C510 Labium majus C511 Labium minus C512 Clitoris C518 Overlapping lesion of vulva C519 Vulva, NOS **Note 1:** This schema is based on the UICC chapter *Vulva,* pages 197-201. * This classification applies to primary carcinomas of the vulva. A carcinoma of the vulva that has extended to the vagina is classified as carcinoma of the vulva **Note 2:** Involvement of the vulva and perineum should be assigned to vulva as the primary site in the absence of a statement that the tumor extended from the perineum to the vulva. This schema only includes C510-C519 (vulva) and does not include primaries of the perineum. Basal and squamous cell carcinomas of the skin of the vulva are coded to C519 and are reportable; basal and squamous carcinomas of the skin of the perineum would be coded to C445 and would not be reportable. **Note 3:** The FIGO stages are based on surgical staging. (TNM stages are based on clinical and/or pathologic classification). **Note 4:** TNM values correspond to the stages accepted by the Federation Internationale de Gynecologic et d'Obstetrique (FIGO). Note that FIGO uses a single stage value which corresponds to different groupings of T, N, and M values. **Note 5:** In addition to directly assigning TNM, Summary Stage 2000 (SS2000) must be captured. If directly assigning SS2000, use the *Vulva* chapter on page 198 of the [SS2000 on-line manual](http://seer.cancer.gov/tools/ssm/SSSM2000-122012.pdf#page=198).

Main Data Items

Name Default Value Used for Staging NAACCR Item Required By Metadata
Clinical T <BLANK> Yes NAACCR #940 None
Clinical N <BLANK> Yes NAACCR #950 None
Clinical M <BLANK> Yes NAACCR #960 None
TNM Clin Stage Group 99 Yes NAACCR #970 None
Pathologic T <BLANK> Yes NAACCR #880 None
Pathologic N <BLANK> Yes NAACCR #890 None
Pathologic M <BLANK> Yes NAACCR #900 None
TNM Path Stage Group 99 Yes NAACCR #910 None
SSF10: FIGO Stage 988 No NAACCR #2864 CCCR/Canada
COC
None
SSF11: Regional Lymph Node - Laterality 999 No NAACCR #2865 CCCR/Canada
SEER
None
SSF12: Pelvic Nodal Status 988 No NAACCR #2866 None None
SSF13: Assessment Method of Pelvic Nodal Status 988 No NAACCR #2867 None None
SSF14: Femoral Inguinal Nodal Status 988 No NAACCR #2868 None None
SSF15: Assessment Method of Femoral Inguinal Nodal Status 988 No NAACCR #2869 None None

Additional Data Items

Name Default Value Used for Staging NAACCR Item Required By Metadata
Year of Diagnosis <BLANK> No NAACCR #390 None
Primary Site <BLANK> Yes NAACCR #400 None
Histology <BLANK> Yes NAACCR #522 None
Behavior <BLANK> Yes NAACCR #523 None
RX Summ Systemic/Surgery Sequence <BLANK> Yes NAACCR #1639 None
RX Summ Surgery/Radiation Sequence <BLANK> Yes NAACCR #1380 None
Regional Nodes Positive <BLANK> Yes NAACCR #820 None

Initial Context

Staging Methods

Expand All | Collapse All

TNM 7 Stage

Inclusion Table

Histology
8000-8246
8248-8576
8940-8950
8980-8981

Start

Additional Context
Clinical Stage Group = 90
Pathologic Stage Group = 90

Next Step

  1. Parse T
  2. clin_t_prefix
    tmp_clin_t

Next Step

  1. Parse N
  2. clin_n_prefix
    tmp_clin_n

Next Step

  1. Parse M
  2. tmp_clin_m
    clin_m_prefix

Next Step

  1. Parse T
  2. tmp_path_t
    path_t_prefix

Next Step

  1. Parse N
  2. tmp_path_n
    path_n_prefix

Next Step

  1. Parse M
  2. tmp_path_m
    path_m_prefix

Next Step

  1. Determine Default T
  2. Source T
    tmp_path_t
    tmp_clin_t
    tmp_combined_t

Next Step

  1. Determine Default N
  2. tmp_combined_n
    tmp_clin_n
    tmp_path_n
    Source N

Next Step

  1. Determine Default M
  2. tmp_path_m
    tmp_combined_m
    tmp_clin_m
    Source M

Next Step

  1. TNM 7 Stage Group
  2. Clinical Stage Group

Next Step

  1. TNM 7 Path Stage Group
  2. Pathologic Stage Group

Next Step

  1. Adjustments for No Clin or No Path
  2. tmp_combined_n
    tmp_combined_m
    Source T
    Clinical Stage Group
    Pathologic Stage Group
    Source N
    tmp_combined_t
    Source M

End

Combined Stage

Inclusion Table

Histology
8000-8246
8248-8576
8940-8950
8980-8981

Start

Additional Context
Combined M = 90
Combined N = 90
Combined Stage Group = 90
Combined T = 90

Next Step

  1. Stop if No Clin and No Path
  2. Combined M
    Combined N
    Source T
    tmp_continue
    Combined T
    Combined Stage Group
    Source N
    ss2017
    Source M

Next Step

  1. Combined T
  2. Source T
    tmp_combined_t

Next Step

  1. Combined N for Tis Cancers
  2. tmp_combined_n
    Source N

Next Step

  1. Combined M
  2. tmp_combined_m
    tmp_source_m
    Source M

Next Step

  1. Determine Combined Prefix
  2. cmb_t_prefix

Next Step

  1. Determine Combined Prefix
  2. cmb_n_prefix

Next Step

  1. Determine Combined Prefix
  2. cmb_m_prefix

Next Step

  1. Concatenate T
  2. Combined T

Next Step

  1. Concatenate N
  2. Combined N

Next Step

  1. Concatenate M
  2. Combined M

Next Step

  1. TNM 7 Path Stage Group
  2. Combined Stage Group

End

Outputs

Name Default Value Description NAACCR Item
Derived Version {{ctx_alg_version}} None
Derived SEER Clin Stage Group 88 NAACCR #3610
Derived SEER Path Stage Group 88 NAACCR #3605
Derived SEER Combined Stage Group 88 NAACCR #3614
Derived SEER Combined T 88 NAACCR #3616
Derived SEER Combined N 88 NAACCR #3618
Derived SEER Combined M 88 NAACCR #3620
Derived SEER Combined T Source <BLANK> NAACCR #3622
Derived SEER Combined N Source <BLANK> NAACCR #3624
Derived SEER Combined M Source <BLANK> NAACCR #3626